美国 - 英文 - NLM (National Library of Medicine)

epic pharma, llc - flecainide acetate (unii: m8u465q1wq) (flecainide - unii:k94fts1806) - in patients without structural heart disease, flecainide acetate tablets, usp are indicated for the prevention of: - paroxysmal supraventricular tachycardias (psvt), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms - paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms flecainide acetate tablets, usp are also indicated for the prevention of: - documented ventricular arrhythmias, such as sustained ventricular tachycardia ( sustained  vt), that in the judgment of the physician are life-threatening. use of flecainide acetate tablets, usp for the treatment of sustained vt, like other antiarrhythmics, should be initiated in the hospital. the use of flecainide acetate tablets, usp is not recommended in patients with less severe ventricular arrhythmias even if the patients are symptomatic. because of the proarrhythmic effects of flecainide acetate tablets, usp, its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment outweigh the risks. flecainide acetate tablets, usp should not be used in patients with recent myocardial infarction. (see boxed warnings.) use of flecainide acetate tablets, usp in chronic atrial fibrillation has not been adequately studied and is not recommended. (see boxed warnings.) as is the case for other antiarrhythmic agents, there is no evidence from controlled trials that the use of flecainide acetate tablets, usp favorably affects survival or the incidence of sudden death. flecainide acetate tablets are contraindicated in patients with pre-existing second- or third-degree av block, or with right bundle branch block when associated with a left hemiblock (bifascicular block), unless a pacemaker is present to sustain the cardiac rhythm should complete heart block occur. flecainide acetate tablets are also contraindicated in the presence of cardiogenic shock or known hypersensitivity to the drug.

美国 - 英文 - NLM (National Library of Medicine)

chartwell rx, llc - flecainide acetate (unii: m8u465q1wq) (flecainide - unii:k94fts1806) - in patients without structural heart disease, flecainide acetate is indicated for the prevention of — paroxysmal supraventricular tachycardias (psvt), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms — paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms flecainide acetate is also indicated for the prevention of — documented ventricular arrhythmias, such as sustained ventricular tachycardia ( sustained vt), that in the judgment of the physician are life-threatening. use of flecainide acetate for the treatment of sustained vt, like other antiarrhythmics, should be initiated in the hospital. the use of flecainide acetate is not recommended in patients with less severe ventricular arrhythmias even if the patients are symptomatic. because of the proarrhythmic effects of flecainide acetate, its use should be reserved for patients in

美国 - 英文 - NLM (National Library of Medicine)

bryant ranch prepack - flecainide acetate (unii: m8u465q1wq) (flecainide - unii:k94fts1806) - in patients without structural heart disease, flecainide acetate tablets usp are indicated for the prevention of: flecainide acetate tablets usp are also indicated for the prevention of: use of flecainide acetate tablets usp for the treatment of sustained vt, like other antiarrhythmics, should be initiated in the hospital. the use of flecainide acetate tablets usp is not recommended in patients with less severe ventricular arrhythmias even if the patients are symptomatic. because of the proarrhythmic effects of flecainide acetate tablets usp, its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment outweigh the risks. flecainide acetate tablets usp should not be used in patients with recent myocardial infarction. (see boxed warnings ). use of flecainide acetate tablets usp in chronic atrial fibrillation has not been adequately studied and is not recommended. (see boxed warnings ). as is the case for other antiarrhythmic agents, there is no evidence from cont

美国 - 英文 - NLM (National Library of Medicine)

bryant ranch prepack - flecainide acetate (unii: m8u465q1wq) (flecainide - unii:k94fts1806) - in patients without structural heart disease, flecainide acetate tablets usp are indicated for the prevention of: flecainide acetate tablets usp are also indicated for the prevention of: use of flecainide acetate tablets usp for the treatment of sustained vt, like other antiarrhythmics, should be initiated in the hospital. the use of flecainide acetate tablets usp is not recommended in patients with less severe ventricular arrhythmias even if the patients are symptomatic. because of the proarrhythmic effects of flecainide acetate tablets usp, its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment outweigh the risks. flecainide acetate tablets usp should not be used in patients with recent myocardial infarction. (see boxed warnings ). use of flecainide acetate tablets usp in chronic atrial fibrillation has not been adequately studied and is not recommended. (see boxed warnings ). as is the case for other antiarrhythmic agents, there is no evidence from cont

美国 - 英文 - NLM (National Library of Medicine)

bryant ranch prepack - flecainide acetate (unii: m8u465q1wq) (flecainide - unii:k94fts1806) - in patients without structural heart disease, flecainide acetate tablets usp are indicated for the prevention of: flecainide acetate tablets usp are also indicated for the prevention of: use of flecainide acetate tablets usp for the treatment of sustained vt, like other antiarrhythmics, should be initiated in the hospital. the use of flecainide acetate tablets usp is not recommended in patients with less severe ventricular arrhythmias even if the patients are symptomatic. because of the proarrhythmic effects of flecainide acetate tablets usp, its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment outweigh the risks. flecainide acetate tablets usp should not be used in patients with recent myocardial infarction. (see boxed warnings ). use of flecainide acetate tablets usp in chronic atrial fibrillation has not been adequately studied and is not recommended. (see boxed warnings ). as is the case for other antiarrhythmic agents, there is no evidence from cont

以色列 - 英文 - Ministry of Health

megapharm ltd - flecainide acetate - solution for injection - flecainide acetate 10 mg/ml - flecainide - flecainide - serious sustained life threatening ventricular arrhthymias that have not respoded to other drugs.

英国 - 英文 - MHRA (Medicines & Healthcare Products Regulatory Agency)

milpharm ltd - flecainide acetate - oral tablet - 50mg

英国 - 英文 - MHRA (Medicines & Healthcare Products Regulatory Agency)

milpharm ltd - flecainide acetate - oral tablet - 100mg

新西兰 - 英文 - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - flecainide acetate 100.008mg;   - modified release capsule - 100 mg - active: flecainide acetate 100.008mg   excipient: capsugel black 01.911 capsugel grey op.c006 capsugel white op colloidal silicon dioxide crospovidone macrogol 400 magnesium stearate methacrylic acid copolymer microcrystalline cellulose povidone purified talc - in patients without structural heart disease and without myocardial infarction, flecainide controlled release capsules are indicated for the prevention of: 1. supraventricular arrhythmias · paroxysmal supraventricular tachycardias (psvt) including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms; · paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms. 2. ventricular arrhythmias · documented life-threatening ventricular arrhythmias such as sustained ventricular tachycardia (vt) if they are considered life-threatening in the judgement of the attending physician. not indicated for less severe ventricular arrhythmias even if symptomatic.

新西兰 - 英文 - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - flecainide acetate 200.016mg;   - modified release capsule - 200 mg - active: flecainide acetate 200.016mg   excipient: capsugel black 01.911 capsugel flesh op.c012 capsugel grey op.c006 colloidal silicon dioxide crospovidone macrogol 400 magnesium stearate methacrylic acid copolymer microcrystalline cellulose povidone purified talc - in patients without structural heart disease and without myocardial infarction, flecainide controlled release capsules are indicated for the prevention of: 1. supraventricular arrhythmias · paroxysmal supraventricular tachycardias (psvt) including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms; · paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms. 2. ventricular arrhythmias · documented life-threatening ventricular arrhythmias such as sustained ventricular tachycardia (vt) if they are considered life-threatening in the judgement of the attending physician. not indicated for less severe ventricular arrhythmias even if symptomatic.